A0002 HT9402-26-Q-9101 Amend.pdf

PDF 136 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Solicitation number
HT9402-26-Q-9101
Issued by

About this file

This document is an amendment to a solicitation issued by the Defense Health Agency (DHA) for Solicitation HT9402-26-Q-9101. The amendment specifically addresses changes to the Pharmacy & Therapeutics (P&T) Committee review schedule for the Antihemophilic Agents – Non Factor Agents class. The impacted pharmaceutical products include Alhemo Pen, Hemlibra, Hympavzi Pen, and Qfitlia, which were originally scheduled for review in the February 2026 P&T meeting but have been moved to the May 2026 P&T meeting. All other terms and conditions of the original solicitation remain unchanged, as confirmed by the Contracting Officer, Marsha L. Petersen, in the document dated January 7, 2026.

View the file

Other files

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

DEFENSE HEALTH AGENCY

7700 ARLINGTON BOULEVARD, SUITE 5101

FALLS CHURCH, VIRGINIA 22042-5101

HT9402-26-Q-9101 0002

January 7, 2026

SUBJECT: AMENDMENT TO SOLICITATION HT9402-26-Q-9101 TO REMOVE THE

ANTIHEMOPHILIC AGENTS CLASS FROM THE FEBRUARY 2026 P&T

1. The purpose of this amendment is to remove the following class/subclass from the list for review during the February 2026 P&T. The class will be moved for review during the May 2026 P&T:

a. Antihemophilic Agents – Non Factor Agents

• Alhemo Pen

• Hemlibra

• Hympavzi Pen

• Qfitlia

2. All other terms and conditions remain the same.

Marsha L. Petersen Contracting Officer

2026-01-08T10:26:29-0600
PETERSEN.MARSHA.LISA.1021485299

File details come from the government source that posted it. Updated .